Skip to main content

Table 2 Adverse events (grades 1 and 2)

From: Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Event Grade 1 Grade 2 Total
Asthenia 4 (16%) 1 (4%) 5 (20%)
Headache 2 (8%) 1 (4%) 3 (12%)
Proteinuria 2 (8%) 0 (0%) 2 (8%)
Hypertension 1 (4%) 1 (4%) 2 (8%)
Diarrhea 2 (8%) 0 (0%) 2 (8%)
Pruritus 0 (0%) 1 (4%) 1 (4%)
Hyporexia 0 (0%) 1 (4%) 1 (4%)
Nausea 0 (0%) 1 (4%) 1 (4%)
Pneumonitis 0 (0%) 1 (4%) 1 (4%)
Thrombosis 0 (0%) 1 (4%) 1 (4%)
Infection 0 (0%) 1 (4%) 1 (4%)
Elevated amylase 1 (4%) 0 (0%) 1 (4%)
Elevated lipase 1 (4%) 0 (0%) 1 (4%)
Rash 1 (4%) 0 (0%) 1 (4%)
Xerosis 1 (4%) 0 (0%) 1 (4%)
Hypothyroidism 1 (4%) 0 (0%) 1 (4%)
Abdominal pain 1 (4%) 0 (0%) 1 (4%)
Vomiting 1 (4%) 0 (0%) 1 (4%)
Pyrexia 1 (4%) 0 (0%) 1 (4%)
Arthralgia 1 (4%) 0 (0%) 1 (4%)
Xerophtalmia 1 (4%) 0 (0%) 1 (4%)